RNA Advances Open New Horizons in Cardiovascular Treatment
RNA-based therapeutics like inclisiran and vutrisiran could redefine treatment paradigms for cardiovascular diseases and related comorbidities.
Related Articles
Cost-Related Non-Adherence Declines for Asthma, More Action Needed
CRN declined from 23.2% to 13.1% between 2011 and 2022 but still affects around 2.5 million adults in the US.
Butterfly-inspired robotic wings fly with no batteries, just magnetic fields
The wings are a mixture of innovative design and magnetic particles that can move without needing batteries or electronics.
Understanding Frontline ABVD in the Real World
An analysis of cHL treatment found that in the real-world setting, interim PET scans were often not being used appropriately for making treatment decisions.
Inside the Florida ghost town that was abandoned for strange reason
A mysterious Florida ghost town – where residents abandoned their homes 62 years ago for a fascinating reason – has suddenly attracted visitors once again.
HONOR MagicBook Art 14: Ultra-Slim Laptop With Snapdragon X Elite
HONOR has unveiled the HONOR MagicBook Art 14 Snapdragon, an ultra-slim laptop powered by the Qualcomm Snapdragon X Elite platform. Weighing…
There’s a true story behind American Primeval—and it’s just as grisly
Suspicion. Rebellion. Murder. The Netflix show American Primeval depicts how tensions between Mormon pioneers in Utah and the U.S. government came to a violent head…
How Elon Musk’s xAI is quietly taking over X
It looks like X is no longer Elon Musk’s favorite child.
Linux kernel source expands beyond 40 million lines – it has doubled in size in a decade
Milestone passed with the debut of Linux 6.14 rc1.
The secret to saying no: A decision framework for physicians
Click on the article title to read more.
Meta’s chief AI scientist says DeepSeek’s success shows that “open source models are surpassing proprietary ones”
Meta’s chief AI scientist, Yann LeCun, says DeepSeek’s success with R1 says more about the value of open source than Chinese competition.
